(Q30317428)

English

Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial.

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

17 June 2017

Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6372099&resulttype=core&format=json

13 May 2020

phase II clinical trial

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Stéphanie Foulon

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6372099&resulttype=core&format=json

13 May 2020

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6372099&resulttype=core&format=json

13 May 2020

Sandrine Faivre

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6372099&resulttype=core&format=json

13 May 2020

15

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6372099&resulttype=core&format=json

13 May 2020

17

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6372099&resulttype=core&format=json

13 May 2020

Jean-Pierre Pignon

22

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6372099&resulttype=core&format=json

13 May 2020

author name string

David Malka

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6372099&resulttype=core&format=json

13 May 2020

Pascale Cervera

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6372099&resulttype=core&format=json

13 May 2020

Christelle de la Fouchardière

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6372099&resulttype=core&format=json

13 May 2020

Eveline Boucher

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6372099&resulttype=core&format=json

13 May 2020

Laetitia Fartoux

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6372099&resulttype=core&format=json

13 May 2020

Jean-Frédéric Blanc

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6372099&resulttype=core&format=json

13 May 2020

Frédéric Viret

10

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6372099&resulttype=core&format=json

13 May 2020

Eric Assenat

11

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6372099&resulttype=core&format=json

13 May 2020

Thomas Herrmann

13

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6372099&resulttype=core&format=json

13 May 2020

Julien Grenier

14

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6372099&resulttype=core&format=json

13 May 2020

Matthias Dollinger

16

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6372099&resulttype=core&format=json

13 May 2020

Philipp Hahn

18

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6372099&resulttype=core&format=json

13 May 2020

Volker Heinemann

19

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6372099&resulttype=core&format=json

13 May 2020

Vanessa Rousseau

20

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6372099&resulttype=core&format=json

13 May 2020

Michel Ducreux

21

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6372099&resulttype=core&format=json

13 May 2020

Dominique Wendum

23

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6372099&resulttype=core&format=json

13 May 2020

Olivier Rosmorduc

24

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6372099&resulttype=core&format=json

13 May 2020

Tim F Greten

25

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6372099&resulttype=core&format=json

13 May 2020

BINGO investigators

26

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6372099&resulttype=core&format=json

13 May 2020

Thomas Seufferlein

12

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6372099&resulttype=core&format=json

13 May 2020

publication date

19 May 2014

1 reference

Europe PubMed Central

17 June 2017

Lancet Oncology Commission

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6372099&resulttype=core&format=json

13 May 2020

15

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6372099&resulttype=core&format=json

13 May 2020

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6372099&resulttype=core&format=json

13 May 2020

819-828

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6372099&resulttype=core&format=json

13 May 2020

Biliary tract cancers.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970212-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970212-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970212-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Gemcitabine and oxaliplatin in advanced biliary tract carcinoma: a phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970212-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Outpatient chemotherapy with gemcitabine and oxaliplatin in patients with biliary tract cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970212-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Gemcitabine and oxaliplatin in patients with unresectable biliary cancer including gall bladder cancer: a Korean Cancer Study Group phase II trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970212-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Best supportive care compared with chemotherapy for unresectable gall bladder cancer: a randomized controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970212-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Activation of the MEK5/ERK5 cascade is responsible for biliary dysgenesis in a rat model of Caroli's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970212-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Bile acids induce cyclooxygenase-2 expression via the epidermal growth factor receptor in a human cholangiocarcinoma cell line

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970212-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Epidermal growth factor receptor immunoreactivity in gallbladder and extrahepatic biliary tract tumours.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970212-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Enhanced epidermal growth factor receptor activation in human cholangiocarcinoma cells

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970212-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Targeting EGFR/HER2 pathways enhances the antiproliferative effect of gemcitabine in biliary tract and gallbladder carcinomas

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970212-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Cetuximab, gemcitabine, and oxaliplatin in patients with unresectable advanced or metastatic biliary tract cancer: a phase 2 study.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970212-8

7 January 2021

based on heuristic

inferred from DOI database lookup

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970212-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Sequential Treatment Assignment with Balancing for Prognostic Factors in the Controlled Clinical Trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970212-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Cetuximab administered once every second week to patients with metastatic colorectal cancer: a two-part pharmacokinetic/pharmacodynamic phase I dose-escalation study.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970212-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Chronomodulated versus fixed-infusion-rate delivery of ambulatory chemotherapy with oxaliplatin, fluorouracil, and folinic acid (leucovorin) in patients with colorectal cancer metastases: a randomized multi-institutional trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970212-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970212-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970212-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Optimal two-stage designs for phase II clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970212-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Gemcitabine alone or in combination with cisplatin in patients with advanced or metastatic cholangiocarcinomas or other biliary tract tumours: a multicentre randomised phase II study - The UK ABC-01 Study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970212-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970212-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970212-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II marker-driven trial of panitumumab and chemotherapy in KRAS wild-type biliary tract cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970212-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Ki-ras mutations as a prognostic factor in extrahepatic bile system cancer. PANK-ras I Project Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970212-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Genetics of biliary tract cancers and emerging targeted therapies

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970212-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II study of erlotinib in patients with advanced biliary cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970212-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1470-2045(14)70212-8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6372099&resulttype=core&format=json

13 May 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6372099&resulttype=core&format=json

13 May 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6372099&resulttype=core&format=json

13 May 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q30317428&oldid=1602625535"